Spotlight
Clinical Role
Clinical
Supplement Spotlight
CME/CE
Subscribe
Expert Addresses Add-On Approach For the Treatment of Chronic Lymphocytic Leukemia
Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses the highlights of the study and how the add-on approach affect the treatment of CLL.
In a Pharmacy Times® interview, Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discussed her ASH 2021 presentation, A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach.
She discussed the highlights of the study and how the add-on approach affect the treatment of CLL.
Recent Videos
Related Content
